Butterfly Network Inc. stocks have been trading up by 13.8 percent after upbeat coverage of its AI-powered ultrasound technology.
Click Here for a Millionaire's POV on Trading BFLY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Midjourney Medical’s new full‑body scanner uses 40 Ultrasound‑on‑Chip modules per system under a Butterfly licensing deal that may deliver up to $74M over five years, with upside from wider adoption.
- Brazil has cleared Butterfly iQ+ and iQ3 devices, and BFLY has begun commercial sales via distributors, opening Latin America’s largest ultrasound market.
- Aleph Neuro’s use of Butterfly’s platform to create high‑resolution 3D brain images showcases the broader potential of Butterfly Embedded beyond point‑of‑care scans.
- Shares of BFLY dropped 18.8% in one session to $7.22, highlighting heavy selling despite ongoing tech wins and market expansion.
- Management will present BFLY’s ultrasound‑on‑chip, software, and licensing roadmap at TD Cowen’s Emerging Growth Call Series on 2026/06/18, a key event for sentiment.
Live Update At 14:02:28 EDT: On Monday, July 06, 2026 Butterfly Network Inc. stock [NYSE: BFLY] is trending up by 13.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BFLY has traded like a momentum name lately. From 2026/06/11 around the mid‑$5s, Butterfly Network climbed into the high‑$8s and low‑$9s by early July, before closing at $8.74 on 2026/07/06. That is a strong short‑term uptrend with plenty of intraday swings for active trading.
The 5‑minute chart shows BFLY grinding higher through the day, with dips toward $8.70 getting bought and spikes above $9 facing some selling. That intraday action tells traders there is real liquidity and active interest, not a dead chart.
Under the hood, Butterfly Network is still a classic high‑growth, high‑loss story. The latest quarter shows revenue of about $26.5M with a healthy 49.2% gross margin, but EBIT margin is deeply negative at around ‑72%. Net loss from continuing operations was roughly $12.7M, and free cash flow ran about ‑$14.8M for the quarter.
More Breaking News
- REAX Jumps As Real Brokerage Tops 35,000 Agents
- Yiren Digital Stock Jumps As Buyback And Insider Control Tighten Float
- Wendy’s Stock Ignites As Meme Traders Target Short Squeeze
- SHAZ Stock Jumps As SharonAI Locks In Massive NVIDIA Deal
On the balance sheet, BFLY has roughly $138M in cash and short‑term investments, low debt, and a current ratio near 4, which buys time to execute. With a price‑to‑sales ratio over 12 and price‑to‑book above 6, traders are clearly paying for future growth and the value of the Ultrasound‑on‑Chip platform rather than present profits.
Why Traders Are Watching BFLY Now
Butterfly Network is not just selling handheld probes anymore. The recent news flow shows BFLY pivoting toward a platform and licensing story, and that is what has traders glued to the tape.
The Midjourney Medical deal is the headline catalyst. BFLY confirmed that Midjourney’s new full‑body tomographic ultrasound scanner ships with 40 Butterfly Ultrasound‑on‑Chip modules per system, under an existing co‑development and licensing agreement. If that scanner gains traction, this arrangement may deliver up to $74M over five years, with future generations expected to pack even more modules per device. For traders, that means leverage: every scanner sold pulls through dozens of BFLY chips, turning each hardware sale into a recurring module opportunity.
At the same time, Brazil is opening up. Butterfly Network cleared local regulators and launched commercial sales of its iQ+ and iQ3 handheld ultrasound devices and app via authorized distributors. That puts BFLY into Latin America’s largest medical device market and one of the fastest‑growing ultrasound regions. The company is positioning these portable systems for both big urban hospitals and underserved rural clinics, which ties directly into the “democratize imaging” theme many growth traders look for.
There is also a tech validation angle. Partner Aleph Neuro used Butterfly’s Ultrasound‑on‑Chip platform to create non‑invasive, high‑resolution 3D brain images. That moves the BFLY story beyond bedside scans into advanced neuroimaging and research. Alongside third‑party commentary naming Butterfly Network a key player in handheld and AI‑driven imaging, the narrative is clear: BFLY sits in the middle of a structural shift toward portable, software‑heavy diagnostics.
Yet the tape has not been smooth. On 2026/06/22, Butterfly Network shares dropped 18.8% in one session to $7.22, a flush that screamed panic or forced selling. A Form 4 later flagged a change in insider or major‑holder ownership, another signal traders watch for sentiment clues. And even the Brazil launch was met with negative same‑day price action, underlining how skittish the market can be with unprofitable growth names.
For disciplined traders, that mix of strong news and sharp pullbacks is exactly what creates opportunity—if you respect the volatility and trade the levels, not the story alone.
Conclusion
BFLY is giving traders a classic high‑beta setup: real catalysts, clear execution risk, and a chart that moves. The combination of the Midjourney Medical licensing deal, Brazil’s commercial rollout, and Aleph Neuro’s 3D brain imaging work all point in the same direction—Butterfly Network wants to be more than a gadget maker. It wants to be the Ultrasound‑on‑Chip backbone behind a range of devices and AI‑powered imaging tools.
Financially, Butterfly Network still burns cash and runs steep operating losses. The latest quarter’s negative margins and ‑$14.8M free cash flow show that profitability is not around the corner. But the company also holds meaningful cash, has low leverage, and is growing revenue at a double‑digit clip, which keeps the growth narrative alive. A TD Cowen Emerging Growth call on 2026/06/18 gives management a public stage to explain how BFLY plans to scale its licensing and embedded strategies and potentially calm nerves after that 18.8% one‑day drop.
For active traders, the key is to avoid falling in love with the story and stay focused on price action. As Tim Sykes likes to say, “Trade the ticker, not the company.” That mindset lines up closely with the discipline many short‑term traders emphasize today—As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. Butterfly Network and BFLY will keep pumping out headlines; your edge comes from studying the chart, respecting risk, and cutting losses fast when the setup breaks. This coverage is for educational and research purposes only, but for those who thrive on volatility and momentum, BFLY remains a name to keep on the screen.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.